Delivery Order SPE2DB22D1202-SPE2DB24FVGL7

Award Date 7/10/24
Potential Completion Date 7/11/24
Potential Value $2.5K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp's Corporate Office Division. The $3,750.84 delivery order contract provides Ondansetron ODT 4 mg tablets to the DLA. This award is associated with a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen and the DLA Troop Support Medical, valued at up to $999,999,999.00 through December 31, 2025. The IDC enables the DLA to efficiently procure a comprehensive range of...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distribution company, to provide Ondansetron ODT 4 mg tablets to the U.S. government. The $3,125.70 Delivery Order contract has a firm fixed price and an ultimate completion date of July 5, 2024. Amerisourcebergen, through its Corporate Office Division, has a significant Indefinite Delivery Contract (IDC) valued up to $999,999,999.00 with the DLA to supply a...
This federal contract award to Amerisourcebergen Drug Corp's Corporate Office division is for the supply of Ondansetron ODT 8 mg tablets to the Defense Logistics Agency (DLA), a defense agency. The contract, valued at $16,900.64, is a Firm Fixed Price Delivery Order with a completion date of July 9, 2024. Amerisourcebergen, a major pharmaceutical distribution company, has a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued up to $999,999,999.00 through...
This federal contract award was granted by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the delivery of Ondansetron ODT 4 mg tablets. The contract, valued at $10,838.21, is a firm fixed-price delivery order with a completion date of January 8, 2024. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999, which serves as a primary vehicle for providing a...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to Amerisourcebergen Drug Corporation's Corporate Office division. The $19,006.49 contract is for the provision of 4,565,032,100 units of the pharmaceutical product Ondansetron ODT 4 mg tablets. This order is part of Amerisourcebergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical valued at up to $999,999,999.00, which serves as the primary vehicle for the company to deliver a...
This federal contract award to AmerisourceBergen Drug Corp is a delivery order valued at $46,836.72 from the Defense Logistics Agency (DLA) for the supply of 4,560,650 units of the drug Ondansetron ODT 4 mg tablet. The contract has a period of performance through April 20, 2023, and utilizes a firm fixed price pricing structure. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as the primary vehicle for providing a...
This federal contract award, valued at $12,349.14, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, which is a Delivery Order (DO) under a larger Indefinite Delivery Contract (IDC) with the DLA, provides for the delivery of Ondansetron ODT 4 mg tablets to support military healthcare programs. The IDC, valued at $999,999,999, serves as a primary vehicle for Amerisourcebergen to...
The U.S. Defense Logistics Agency (DLA) awarded a $14,550.99 firm-fixed-price delivery order to AmerisourceBergen Drug Corp's Corporate Office division. The order is for the supply of 4,564,299,405 units of the pharmaceutical product Ondansetron ODT 8 mg Tablets. This award is part of a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with DLA Troop Support Medical, valued up to $999,999,999.00 through December 2025. The IDC enables DLA to efficiently procure essential...
This federal contract award, valued at $1,631.35, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp's Corporate Office division. The contract is for the delivery of Ondansetron ODT 4 mg tablets. Amerisourcebergen, a major pharmaceutical distributor, holds an Indefinite Delivery Contract (IDC) with DLA Troop Support Medical valued at up to $999,999,999.00 through December 31, 2025. This single-award IDC serves as the primary vehicle for Amerisourcebergen to deliver a...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, a $1,382.44 delivery order, is for the supply of 4,568,052,647 units of the medication Ondansetron ODT 4 mg tablets. The contract has an ultimate completion date of April 29, 2025 and is a firm fixed-price arrangement. This award is not associated with a set-aside program. Amerisourcebergen Drug Corp holds...
  • SPE2DB22D1202
    Indefinite Delivery Contract
  • SPE2DB22D1202-SPE2DB24FVGL7
    Delivery Order

The federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corporation's Corporate Office division. The $2,500.56 Delivery Order contract is for the supply of Ondansetron ODT 4 mg tablets to DLA facilities. This award is part of Amerisourcebergen's larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued up to $999,999,999.00 through December 2025. The IDC enables the DLA to efficiently procure a comprehensive range of pharmaceutical products and medical supplies, including specialty, brand name, generic, and over-the-counter medications, as well as critical care materials, in support of the Department of Defense's medical treatment programs and facilities worldwide. This contract does not have a set-aside designation.

Generated 10/9/24, 9:28 AM